Respiratory syncytial virus infections
Pneumologe, ISSN: 1613-6055, Vol: 16, Issue: 4, Page: 232-241
2019
- 2Citations
- 334Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Review Description
Respiratory syncytial virus (RSV) is a seasonally occurring, worldwide distributed airway pathogen and the most common cause for severe bronchiolitis and pneumonia in infants. The RSV affects all age groups but in premature infants, immunodeficient patients and older people over the age of 65 years it is associated with a significant morbidity and mortality. No specific antiviral treatment is so far available and RSV bronchiolitis treatment remains only supportive with oxygen and fluid supplementation and non(invasive) ventilation. A passive immunization with palivizumab, a monoclonal antibody administered during the RSV season, is indicated in high-risk patients for avoidance of severe courses. Currently, however, many novel active RSV vaccines and antiviral substances are being clinically tested and should become available in the upcoming years.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85067677960&origin=inward; http://dx.doi.org/10.1007/s10405-019-0252-8; http://link.springer.com/10.1007/s10405-019-0252-8; http://link.springer.com/content/pdf/10.1007/s10405-019-0252-8.pdf; http://link.springer.com/article/10.1007/s10405-019-0252-8/fulltext.html; https://dx.doi.org/10.1007/s10405-019-0252-8; https://link.springer.com/article/10.1007/s10405-019-0252-8
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know